{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:40:56Z","timestamp":1763620856072,"version":"3.37.3"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Martin Luther University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Vitamin K antagonists (VKAs) are still in use for oral anticoagulation, but not all indications allow their replacement by direct oral anticoagulants. Although formal dose reduction is not required in patients with impaired kidney function, case reports indicate that acute kidney injury (AKI) might be associated with derailment of VKA therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study retrospectively collected patients from a tertiary nephrology care centre who experienced AKI while being treated with VKA. In these individuals, the international normalized ratio (INR) as a measure of anticoagulant effect during renal failure was compared with a reference time point with stable kidney function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 100 patients with AKI and ongoing VKA therapy met the inclusion criteria. The majority (76%) of patients had AKI with CKD. Volume depletion (n\u2009=\u200943), septic renal failure (n\u2009=\u200922), decompensated heart failure (n\u2009=\u200918) and toxic renal damage (n\u2009=\u200911) were the most important causes of AKI. The average INR values at the time of AKI were higher than at the reference time point [median 3.17 (range 1.10\u201313.0) versus 2.24 (1.07\u20135.17); P\u2009&amp;lt;\u20090.0001]. Fifty-four patients had INR values above the recommended therapeutic range for their indication at the time point of AKI. Bleeding complications occurred in 24 patients during AKI and the VKA dose had to be reduced in 55. Women, patients with low body mass index and patients with diabetes were predisposed to overanticoagulation during AKI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The effect of AKI on anticoagulation by VKA has not been systematically described. This risk should be considered in patients at high risk for AKI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfab008","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T22:34:32Z","timestamp":1610490872000},"page":"681-686","source":"Crossref","is-referenced-by-count":3,"title":["Risk of overanticoagulation during acute kidney injury in patients treated with vitamin K antagonists"],"prefix":"10.1093","volume":"37","author":[{"given":"Luisa","family":"S\u00fcfling","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Greinert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2823-0847","authenticated-orcid":false,"given":"Matthias","family":"Girndt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"2022032512312277000_gfab008-B1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2014.11.004","article-title":"Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study","volume":"65","author":"Limdi","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2022032512312277000_gfab008-B2","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1681\/ASN.2009030319","article-title":"Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation","volume":"20","author":"Chan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022032512312277000_gfab008-B3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1378\/chest.15-1719","article-title":"Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies","volume":"149","author":"Dahal","year":"2016","journal-title":"Chest"},{"key":"2022032512312277000_gfab008-B4","first-page":"1012","article-title":"Can acute renal insufficiency increase the effect of warfarin?","volume":"171","author":"Arnason","year":"2009","journal-title":"Ugeskr Laeger"},{"key":"2022032512312277000_gfab008-B5","first-page":"8","article-title":"Kidney Disease: Improving Global Outcomes Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2022032512312277000_gfab008-B6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022032512312277000_gfab008-B7","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2022032512312277000_gfab008-B8","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2022032512312277000_gfab008-B9","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2022032512312277000_gfab008-B10","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/archinte.160.11.1612","article-title":"Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation","volume":"160","author":"Hylek","year":"2000","journal-title":"Arch Intern Med"},{"key":"2022032512312277000_gfab008-B11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2022032512312277000_gfab008-B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1476-5381.1979.tb13676.x","article-title":"Decreased binding of drugs and dyes to plasma proteins from rats with acute renal failure: effects of ureter ligation and intramuscular injection of glycerol","volume":"66","author":"Bowmer","year":"1979","journal-title":"Br J Pharmacol"},{"key":"2022032512312277000_gfab008-B13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00561784","article-title":"Influence of acute renal failure on the protein binding of drugs in animals and in man","volume":"11","author":"Belpaire","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"key":"2022032512312277000_gfab008-B14","first-page":"468","article-title":"Influence of renal dysfunction on warfarin plasma protein binding","volume":"16","author":"Bachmann","year":"1976","journal-title":"J Clin Pharmacol"},{"key":"2022032512312277000_gfab008-B15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","article-title":"The effect of chronic renal failure on drug metabolism and transport","volume":"4","author":"Dreisbach","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2022032512312277000_gfab008-B16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/bja\/71.2.282","article-title":"Effect of renal failure on drug metabolism by the liver","volume":"71","author":"Elston","year":"1993","journal-title":"Br J Anaesth"},{"key":"2022032512312277000_gfab008-B17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0009-9236(03)00015-8","article-title":"Cytochrome P4502C9 activity in end-stage renal disease","volume":"73","author":"Dreisbach","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"2022032512312277000_gfab008-B18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0009-9236(03)00056-0","article-title":"Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease","volume":"73","author":"Dowling","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"2022032512312277000_gfab008-B19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.1365-2141.2003.04110.x","article-title":"Oral anticoagulants in the elderly","volume":"120","author":"Froom","year":"2003","journal-title":"Br J Haematol"},{"key":"2022032512312277000_gfab008-B20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamainternmed.2013.13957","article-title":"Warfarin interactions with antibiotics in the ambulatory care setting","volume":"174","author":"Clark","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2022032512312277000_gfab008-B21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"2022032512312277000_gfab008-B22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s11606-006-0064-5","article-title":"Anticoagulation control in the peri-hospitalization period","volume":"22","author":"van Walraven","year":"2007","journal-title":"J Gen Intern Med"},{"key":"2022032512312277000_gfab008-B23","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1681\/ASN.2018070741","article-title":"Anticoagulant-related nephropathy","volume":"29","author":"Brodsky","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022032512312277000_gfab008-B24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2215\/CJN.13251118","volume":"14","author":"Sevillano","year":"2019","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfab008\/36332337\/gfab008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/4\/681\/42973065\/gfab008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/4\/681\/42973065\/gfab008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T17:03:04Z","timestamp":1648227784000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/4\/681\/6103794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,1,18]]},"published-print":{"date-parts":[[2022,3,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfab008","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"type":"print","value":"0931-0509"},{"type":"electronic","value":"1460-2385"}],"subject":[],"published-other":{"date-parts":[[2022,4]]},"published":{"date-parts":[[2021,1,18]]}}}